Brickroad
Brickroad
IndexSignalsBlog
/Index//

Product

  • Information Frontier Agent
  • Vendor Management Agent
  • Product Tour
  • Pricing

Solutions

  • All Solutions
  • Atlas
  • Wayfinder
  • Horizon

Suppliers

  • Sell Your Data
  • Start Onboarding
  • Programmatic Data License

Community

  • Public Index
  • Signals
  • Blog

Company

  • About
  • Team
  • Careers
  • Brand

Connect

  • LinkedIn
  • X
PrivacyTermsCookies

© 2026 Brickroad

/Index/Kitsa/Editorially triaged clinical-trial event stream
K

Editorially triaged clinical-trial event stream

KITSAManage supplier listing

Editorially triaged clinical-trial event stream: every ~14 days the full new-registration universe is screened and a fixed slate of 15 'high-signal' trials is selected and written up with sponsor, phase, population/age bracket, modality class, indication, comparator and trial size. The licensable asset is the selection/triage layer plus per-trial structured attributes and first-in-class flags (e.g. largest mRNA-vaccine efficacy trial ever registered, first in vivo CD19 CAR-T, first clinical prime-editing trial), not the registry records themselves.

Open buyer room →
Kitsa/Editorially triaged clinical-trial event stream
SampleCoverage

Sample

Brickroad customers

Sample this dataset before you buy it.

Your sourcing agent asks Kitsa and files the sample in your catalog — private to you.

Start 7-day trial→Nothing is charged until the trial ends.

Coverage

Universe, instruments and categories.

Industry
Health Care TechnologyApplication Software
Instruments
equities
Categories
Alternative
Fundamental
Sentiment
Regions
USUKChina/HK
Sample tickers
GSKLLYAZNAMGNPFEREGNARGXCRSPPRMEINCY
Dataset card
Type
not stated
Format
Long-form editorial text (HTML/email briefs) with semi-structured per-trial records grouped under anchored therapeutic-area sections (Oncology, Cardiometabolic, Immunology & Respiratory, Advanced Modalities); no published bulk feed or API
Volume
~255 curated trial write-ups to date (17 editions x 15 trials) with per-trial structured attributes and editorial rationale, produced against a screening universe of the full public registry (~550K+ registered studies screened each fortnight); ~26 editions per year at the current cadence
Users
Est. 1K-10K subscribers — niche professional biotech/pharma newsletter (inferred from a specialised B2B audience, a bi-weekly cadence, no published subscriber count, and a free inbox-subscription signup rather than a paid seat)
History
not stated
Update frequency
not stated
Growth
Active — edition 17 published 15 September 2026, edition 16 on 31 August 2026, i.e. an unbroken roughly fortnightly cadence through the current month with no gaps in the archive
Launched
Trial Watch ~late 2025 / early 2026 (edition 17 is dated 15 September 2026 on a twice-monthly cadence, which back-casts edition 1 to roughly December 2025-January 2026); the parent company likely predates the publication, but no earlier dated artifact appears on the site
Delivery
not stated
Entity mapping
not stated
Sample
not stated
Point-in-time
not stated
Licence
not stated

supplier index read from their site

Kitsa has not added their own details yet. Not yet on file:

  • Dataset
  • Data dictionary
  • Coverage
  • Provenance
  • Rights & data handling